XSpray Pharma AB (OSTO:XSPRAY) Debt-to-Asset : 0.05 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is XSpray Pharma AB Debt-to-Asset?

XSpray Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr5.05 Mil. XSpray Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr28.56 Mil. XSpray Pharma AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was kr667.70 Mil. XSpray Pharma AB's debt to asset for the quarter that ended in Sep. 2024 was 0.05.

XSpray Pharma AB Debt-to-Asset Historical Data

The historical data trend for XSpray Pharma AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Debt-to-Asset Chart

XSpray Pharma AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.05

XSpray Pharma AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															-	0.05	0.05	0.05	0.05

Competitive Comparison of XSpray Pharma AB's Debt-to-Asset

For the Biotechnology subindustry, XSpray Pharma AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XSpray Pharma AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's Debt-to-Asset falls into.

XSpray Pharma AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

XSpray Pharma AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.861	+	31.947)	/	765.263
	=	0.05

XSpray Pharma AB's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.045	+	28.561)	/	667.696
	=	0.05

XSpray Pharma AB (OSTO:XSPRAY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

XSpray Pharma AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

XSpray Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (OSTO:XSPRAY) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

6XP:Germany

Address

Scheeles vag 2, Solna, SWE, SE-171 65

Website

https://www.xspraypharma.com

XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and XS00Y.

XSpray Pharma AB Headlines

No Headlines